Jean-Yves Pavee retired from the board last night and has been replaced by Jeff Barton, who has been nominated by Abbott Laboratories.
Barton currently serves as vice president of licensing and acquisitions at Abbott.
During his time in this role, Abbott has executed several strategically important transactions including the acquisition of St. Jude Medical, CFR Pharmaceuticals and Veropharm.
“He brings extensive commercial experience, particularly in the United States, which will be valuable to our company as we continue to execute our global strategy. We also wish to take this opportunity to thank Jean-Yves for his contribution and support to Allergy Therapeutics since 2014," said Peter Jensen, chairman of Allergy Therapeutics.